Publications en collaboration avec des chercheurs de Hospital Universitario La Paz (13)

2024

  1. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

    Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326

  2. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

  3. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049

  4. The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

    Clinical and Translational Oncology, Vol. 26, Núm. 2, pp. 352-362

2021

  1. Pan-TRK immunohistochemistry an example-based practical approach to efficiently identify patients with NTRK fusion cancer

    Archives of Pathology and Laboratory Medicine, Vol. 145, Núm. 8, pp. 1031-1040

  2. Targeted therapy moves to earlier stages of non-small-cell lung cancer: Emerging evidence, controversies and future challenges

    Future Oncology, Vol. 17, Núm. 30, pp. 4011-4025

2020

  1. A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens

    Cancer Cytopathology, Vol. 128, Núm. 12, pp. 928-938

  2. Immunotherapy moves to the early-stage setting in non-small cell lung cancer: Emerging evidence and the role of biomarkers

    Cancers, Vol. 12, Núm. 11, pp. 1-21

  3. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 167-181

  4. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Clinical and Translational Oncology, Vol. 22, Núm. 7, pp. 989-1003

2019

  1. Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132

2014

  1. Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry

    PLoS ONE, Vol. 9, Núm. 9

2013

  1. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer

    Oncogene, Vol. 32, Núm. 10, pp. 1274-1283